07:00 , Sep 5, 2016 |  BC Week In Review  |  Clinical News

CAP-1002: Preliminary Phase I data

Preliminary data from 12 evaluable patients with New York Heart Association (NYHA) Class III heart failure in the open-label, dose-escalation Phase Ia portion of the U.S. Phase Ia/b DYNAMIC trial showed that intracoronary infusions of...
07:00 , Apr 6, 2015 |  BC Week In Review  |  Clinical News

IV Bendavia: Phase II data

The double-blind, international Phase II EMBRACE trial in 297 patients who have undergone successful coronary intervention and stenting for ST-segment elevation myocardial infarction (STEMI) showed that 0.05 mg/kg/hour IV Bendavia led to a lower AUC...
07:00 , Mar 18, 2013 |  BC Week In Review  |  Clinical News

Inclacumab: Phase II data

The double-blind, international Phase II SELECT-ACS trial in 322 evaluable patients with NSTEMI who underwent PCI showed that a single IV infusion of 20 mg/kg inclacumab missed the co-primary endpoints of reducing cardiac troponin I...
07:00 , Jul 16, 2012 |  BC Week In Review  |  Company News

Alere sales and marketing update

Alere began recalling lots of Alere's Triage products following reports of decreased precision leading to false positive and false negative results. The recall includes Triage CardioProfiler Panel, Triage Cardiac Panel, Triage Profiler...
07:00 , Jul 4, 2011 |  BC Week In Review  |  Clinical News

CMX-2043: Phase IIa data

Top-line data from a double-blind, placebo-controlled Phase IIa trial in patients undergoing PCI showed that IV CMX-2043 demonstrated a favorable safety profile at all 3 dose levels tested, which Ischemix said met the primary endpoint...
07:00 , Sep 27, 2010 |  BC Week In Review  |  Company News

Roche sales and marketing update

Roche's Roche Diagnostics subsidiary launched a series of STAT immunoassays for cardiac biomarker testing for use on its cobas 6000 analyzer. The new 9-minute assays include troponin T, troponin I, creatine kinase MB, myoglobin...
07:00 , Mar 15, 2010 |  BC Week In Review  |  Clinical News

CMX-2043: Phase IIa started

Ischemix began a double-blind, placebo-controlled, U.S. and Indian Phase IIa trial to evaluate 0.8, 1.6, and 2.4 mg/kg intravenous CMX-2043 in 220 patients. Ischemix, Maynard, Mass.   Product: CMX-2043   Business: Cardiovascular   Molecular target: Protein kinase...
08:00 , Nov 23, 2009 |  BC Week In Review  |  Clinical News

Serp-1: Phase IIa data

In a double-blind, placebo-controlled Phase IIa trial in 48 patients, IV VT-111 met its primary safety endpoint with no drug-related serious adverse events. VT-111 also significantly reduced levels of the cardiac damage biomarkers troponin I...
07:00 , May 11, 2009 |  BC Week In Review  |  Company News

Inverness sales and marketing update

Inverness' Biosite Inc. subsidiary voluntarily recalled one lot of its Triage Cardiac Panel to diagnose myocardial infarction. Biosite said quality control testing of the lot showed low recovery of creatine kinase MB, troponin...
07:00 , Jun 30, 2008 |  BC Week In Review  |  Company News

Response Biomedical, Roche sales and marketing update

Roche's Roche Diagnostics division received exclusive, worldwide marketing rights to Response BioMedical's cardiovascular point-of-care (POC) diagnostics, including: RAMP Troponin I Test, which measures cardiac troponin I levels; RAMP NT-proBNP Test, which assists in...